__NUXT_JSONP__("/drugs/Gemtuzumab_Ozogamicin", (function(a,b,c,d,e){return {data:[{drug:{slug:c,emaEpar:[{activeSubstance:a,conditionIndication:"Mylotarg is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).",inn:a,marketingAuthorisationDate:"2018-04-19 00:00:00",marketingAuthorisationHolder:"Pfizer Europe MA EEIG",medicineName:b,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fmylotarg-0"}],fdaDrugLabel:[{brand:b,indication:"1 INDICATIONS AND USAGE MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older ( 1.1 ). treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older ( 1.2 ). 1.1 Newly-Diagnosed CD33-positive Acute Myeloid Leukemia (AML) MYLOTARG is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older. 1.2 Relapsed or Refractory CD33-positive AML MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and pediatric patients 2 years and older.",manufacturer:"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.",splSetId:"32fd2bb2-1cfa-4250-feb8-d7956c794e05"}],id:c,nciThesaurus:{casRegistry:"220578-59-6",chebiId:"",chemicalFormula:"C73H96IN6O25S3",definition:"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis.",fdaUniiCode:"8GZG754X6M",identifier:"C1806",preferredName:d,semanticType:"Immunologic Factor",subclassOf:["C2333"],synonyms:["CDP-771","CMA-676","Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody","GEMTUZUMAB OZOGAMICIN",d,b,"WAY-CMA-676","gemtuzumab",a,"hP67.6-Calicheamicin"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FGemtuzumab_Ozogamicin",extension:".json",createdAt:e,updatedAt:e}}],fetch:{},mutations:void 0}}("gemtuzumab ozogamicin","Mylotarg","Gemtuzumab_Ozogamicin","Gemtuzumab Ozogamicin","2021-10-30T13:36:43.943Z")));